Praxis licenses ulixacaltamide to Tenacia for Greater China; PRAX-628 Phase 2a PPR data positive; $81.3M cash

Praxis Precision Medicines, Inc.

Entered exclusive collaboration with Tenacia Biotechnology for ulixacaltamide in essential tremor in Greater China.
Issued 443,253 shares to BCPE (Bain Capital affiliate) at $22.5605/share (~20% premium) for $10M aggregate.
Preliminary cash and equivalents as of Dec 31, 2023: $81.3 million.
PRAX-628 Phase 2a PPR study: preliminary analysis of 15 mg cohort exceeded expectations; full data Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.